MedTrace Logo

Biomarkers in the Evaluation of Chronic Lung Disease

NCT00926523 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 67

Last updated 2011-05-27

No results posted yet for this study

Summary

We hypothesize that hypoxia-induced pulmonary vascular remodeling is mediated by macrophage migration inhibitory factor (MIF), that remodeling is in fact the reflection of a chronic inflammatory process, and that MIF may be a useful biomarker of the severity and progression of both ILD and PH.

Conditions

Interventions

OTHER

Blood Gas

Subject will have both venous and arterial blood draws to assess for the bloods content of MIF

OTHER

Pulmonary Exercise Test

Subject will ride exercise bike to assess their pulmonary function level.

OTHER

Spirometry

To assess subjects lung function

OTHER

Breath Condensate Collector

Subject with use breathing apparatus to allow researchers to collect breath condensate to assess level of MIF in breathe condensate.

Sponsors & Collaborators

  • Northwell Health

    lead OTHER

Principal Investigators

  • Arunabh Talwar, M.D. · Northwell Health

  • Ed Miller, Ph.D · North Shore Long Island Jewish Healthy System

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-06-30
Primary Completion
2011-03-31
Completion
2011-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00926523 on ClinicalTrials.gov